File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.apsb.2020.12.020
- Scopus: eid_2-s2.0-85105062081
- PMID: 34589395
- WOS: WOS:000701202400013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
Title | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management |
---|---|
Authors | |
Keywords | Chinese medicine Herbal medicine Diabetic nephropathy Diabetic kidney disease Signaling pathway |
Issue Date | 2021 |
Publisher | Elsevier, published in association with Institute of Materia Medica and Chinese Pharmaceutical Association. The Journal's web site is located at http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b |
Citation | Acta Pharmaceutica Sinica B, 2021, v. 11 n. 9, p. 2749-2767 How to Cite? |
Abstract | Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN. |
Persistent Identifier | http://hdl.handle.net/10722/305129 |
ISSN | 2023 Impact Factor: 14.7 2023 SCImago Journal Rankings: 3.035 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | TANG, G | - |
dc.contributor.author | Li, S | - |
dc.contributor.author | ZHANG, C | - |
dc.contributor.author | Chen, H | - |
dc.contributor.author | Wang, N | - |
dc.contributor.author | Feng, Y | - |
dc.date.accessioned | 2021-10-05T02:40:08Z | - |
dc.date.available | 2021-10-05T02:40:08Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Acta Pharmaceutica Sinica B, 2021, v. 11 n. 9, p. 2749-2767 | - |
dc.identifier.issn | 2211-3835 | - |
dc.identifier.uri | http://hdl.handle.net/10722/305129 | - |
dc.description.abstract | Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN. | - |
dc.language | eng | - |
dc.publisher | Elsevier, published in association with Institute of Materia Medica and Chinese Pharmaceutical Association. The Journal's web site is located at http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b | - |
dc.relation.ispartof | Acta Pharmaceutica Sinica B | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Chinese medicine | - |
dc.subject | Herbal medicine | - |
dc.subject | Diabetic nephropathy | - |
dc.subject | Diabetic kidney disease | - |
dc.subject | Signaling pathway | - |
dc.title | Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management | - |
dc.type | Article | - |
dc.identifier.email | Chen, H: haiyong@hku.hk | - |
dc.identifier.email | Wang, N: ckwang@hku.hk | - |
dc.identifier.email | Feng, Y: yfeng@hku.hk | - |
dc.identifier.authority | Chen, H=rp01923 | - |
dc.identifier.authority | Wang, N=rp02075 | - |
dc.identifier.authority | Feng, Y=rp00466 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1016/j.apsb.2020.12.020 | - |
dc.identifier.pmid | 34589395 | - |
dc.identifier.pmcid | PMC8463270 | - |
dc.identifier.scopus | eid_2-s2.0-85105062081 | - |
dc.identifier.hkuros | 326193 | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | 2749 | - |
dc.identifier.epage | 2767 | - |
dc.identifier.isi | WOS:000701202400013 | - |
dc.publisher.place | China | - |